Veradigm Introduces Cardiometabolic Clinical Registry Datasets to Enhance the Next Generation of Real-World Research

February 18, 2025

With the introduction of seven new disease-specific registry datasets, Veradigm is enabling deep, targeted research to drive innovation and enhance real-world clinical insights

CHICAGO--(BUSINESS WIRE)--Feb. 18, 2025-- Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today the launch of its disease-specific cardiometabolic Clinical Data Registry datasets, which contain de-identified information about patients' health and care for a specific condition or disease. These datasets provide researchers with access to specialty, Natural Language Processing (NLP)-enhanced real-world data to advance the understanding of patient insights and clinical details to support research throughout the drug development life cycle.

Veradigm's Clinical Data Registries harmonize data from over 80 different electronic health records (EHRs) into a research ready data model, leveraging both structured and unstructured data to provide precise insights into disease patterns, treatment outcomes, and patient care.

Veradigm's new cardiometabolic disease registry cohorts include:

- Heart Failure Registry
- Atrial Fibrillation Registry
- ASCVD Registry
- Hypertension Registry
- Type 1 Diabetes Registry
- Type 2 Diabetes Registry
- Chronic Kidney Disease Registry

"Globally, cardiovascular disease and metabolic disorders are the number one leading cause of death," said Stuart Green, Senior Vice President & General Manager of Life Sciences Business at Veradigm. "We've leveraged NLP to extract insights from unstructured and semi-structured clinical data to generate evidence, particularly looking for clinical details that are important for life science researchers, public health and government regulators."

About Veradigm®

Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, *Insightfully*, visit www.veradigm.com, or find Veradigm on LinkedIn, Facebook, Twitter, Instagram, and YouTube.

© 2025 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250218122163/en/

Investors:
Jenny Gelinas
312-506-1237
jenny.gelinas@veradigm.com

Media:
Concetta Rasiarmos
630-740-3152
concetta.rasiarmos@veradigm.com

Source: Veradigm